---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-041706"
form_type: "8-K"
ticker: "AZTR"
cik: "0001701478"
company_name: "Azitra, Inc."
filed_at: "2026-09-08T12:05:29+00:00"
generated_at: "2026-09-08T12:10:18.749288+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Azitra to present at H.C. Wainwright conference; update on ATR-COSF and ATR-04

## Summary
- COO Travis Whitfill to present virtually at H.C. Wainwright 28th Annual Global Investment Conference, Sept 14-16, 2026.
- Presentation will include initial data from ATR-COSF program for cosmetic applications targeting fine lines and wrinkles.
- Will discuss continued enrollment in first cohort of Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated rash.
- ATR-04 has FDA Fast Track designation; EGFRi rash impacts ~150,000 people in U.S.

## SEC filing metadata
- accession: 0001493152-26-041706
- form_type: 8-K
- ticker: AZTR
- cik: 0001701478
- company_name: Azitra, Inc.
- filed_at: 2026-09-08T12:05:29+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701478/000149315226041706/0001493152-26-041706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701478/000149315226041706/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-041706
- JSON: https://secwatch.observer/filing/0001493152-26-041706.json
- Plain text: https://secwatch.observer/filing/0001493152-26-041706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.